Overview

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses testosterone) given prior to surgery can decrease the chance that cancer will come back compared to degarelix alone. People who usually have this type of prostate cancer usually do not receive any additional therapy prior to surgery. Approximately 24 individuals will be asked to participate in this study.

Phase:

Early Phase 1

Details

Lead Sponsor:

Charles G. Drake
Matthew Dallos

Collaborators:

Bristol-Myers Squibb
Ferring Pharmaceuticals